Cephalon Makes A $130 Mil. Bet On Mesoblast's Stem Cell Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. specialty pharma continues its multi-year effort to expand into biologics by licensing in the Australian biotech's adult stem cell technology for cardiovascular, oncology, and neurodegenerative indications.
You may also be interested in...
Valeant's Bid For Cephalon: Will Opportunism Trump Innovation?
Valeant Pharmaceutical International Inc.'s hostile bid for Cephalon Inc. has all the earmarks of a pharma battle of our times: it pits an R&D-adverse, opportunistic company against a specialty pharma company that is increasingly betting on mid-to-long term innovation.
Valeant's Bid For Cephalon: Will Opportunism Trump Innovation?
Valeant Pharmaceutical International Inc.'s hostile bid for Cephalon Inc. has all the earmarks of a pharma battle of our times: it pits an R&D-adverse, opportunistic company against a specialty pharma company that is increasingly betting on mid-to-long term innovation.
As Cephalon Rejects Valeant Bid, Valeant Officially Goes Hostile
Valeant's offer undervalues Cephalon, its assets and its prospects, and "ignores the proven ability" of its management to maximize opportunities, Cephalon's board says.